Diagnosis of Whooping Cough-Cruickshank et al. DBICAJL 639 the diagnosis of whooping cough was confirmed by isolating B. pertussis the complement fixation test seemed rather more sensitive than the agglutination test in detecting rising antibody titres. Thus, when the complement fixation technique is convenient and practical, as in virus laboratories where paired sera from children with respiratory infections are tested against a battery of complement fixation antigens, a B. pertussis antigen could be useful. We found that the age of the patient was of considerable importance in relation to both B. pertussis isolations and serological responses. Under 6 months of age isolation of B. pertussis was much conmnoner than positive serological findings; over 1 year of age serological tests were more often positive than were cultures. Our study suggests that two agerelated factors were involved in this difference-namely, a poor or delayed antibody response by the young infant as has been previously reported in other respiratory infections (Grist, 1957; Chanock et al., 1961; Ross et al., 1964) and the low proportion of children under 6 months of age who had been fully immunized against B. pertussis. In some children previous immunization appeared to have suppressed growth of B. pertussis in the nasopharynx but not the serological response.
The preponderance of serotype 1,3 in both immunized and unimmunized patients is in keeping with previous findings reported by Preston (1963 Preston ( , 1965 and by the Public Health Laboratory Service Whooping Cough Committee and Working Party (1969) . These reports indicated that the efficacy of much of the pertussis vaccine in use for some years before 1968 required improvement. Though since 1964 all manufacturers in the United Kingdom have included strains 1,3 in their B. pertussis vaccines (British Medical 7ournal, 1969) it would appear from the clinical and bacteriological findings of the present study that current whooping cough vaccines are still not adequately protective against strain 1,3.
We wish to thank Mr. K. Begg, Mr. S. McMichael, and Mr. D. Veitch, for valuable technical help; many general practitioners and medical officers of health for immunization particulars; and clinical colleagues for collection of sera. S ummary: All our patients with a recent thromboembolic occlusion of limb arteries treated with streptokinase have been reviewed retrospectively. Clearing of the main artery, as judged by arteriography or reappearance of arterial pulsations, occurred more often when treatment was started early. If only patients with an iliac, femoral, or popliteal artery occlusion are considered, those who received a lower initial dose had a significantly higher clearing rate and a significantly lower mortality than those who received a high initial dose (500,000 units of streptokinase or more). Therefore an initial standard dose of 1,200,000 units of streptokinase is no longer recommended in these conditions, and even an individually titrated initial dose of more than half a million units could be hazardous. If no neurological abnormalities were present on admission amputation was never necessary, even if clearing of the main artery did not occur. If there was sensory loss of at least part of a limb, amputation was avoided only if the pulsations returned in at least one artery of hand or foot.
Introduction
During the administration of streptokinase in patients with a recent thromboembolic occlusion of a limb artery, patency of the main artery can be restored (Fletcher et al., 1959; Gross et al., 1960; Kahn et al., 1961; Cotton et al., 1962; Nilsson and Olow, 1962; McNicol et al., 1963; Salmon et al., 1963; Schmutzler, 1963 Schmutzler, , 1968 Verstraete et al., 1963; Winckelmann et al., 1963; Marchal et al., 1964; Haan and Tilsner, 1965; Hess, 1967) . Nevertheless, neither the incidence of spontaneous disobstruction nor the optimal dose and duration of streptokinase therapy have yet been established. Furthermore, no controlled study is available that compares the value of streptokinase treatment with other current therapeutic regimens.
We have shown (Verstraete et al., 1966) , on the basis of arteriographic studies, that in these patients patency of the main artery can be obtained after administration of streptokinase according to the following standard dosage scheme: a set initial dose of 1,250,000 units and a maintenance dose of 100,000 units/hour for 72 hours. Since then more patients have been treated by this method. The aim of this paper is to describe the outcome in patients in whom recent thromboembolic occlusion of a limb artery was treated with streptokinase, and to compare the results obtained using a high initial dose with those obtained with a moderate initial dose. Biochemical changes in the plasma during the different types of streptokinase administration have been reported elsewhere (Amery, 1969) .
Methods (1) Patient Selection and General Condition
Eighty-five patients treated with streptokinase for thromboembolic occlusion of a limb artery or the abdominal aorta have been studied retrospectively; some have already been reported (Verstraete et al., , 1964 (Verstraete et al., , 1966 . The patients were divided into three groups according to their general condition at admission, using the following criteria: Grade 1. Good general condition: the patient was ambulant until just before the acute episode and the general condition on admission was good-that is, one of the criteria mentioned below was not fulfilled.
Grade 2. Bad general condition: patients with heart failure, with or without auricular fibrillation, severe angina, or recent myocardial infarction, oxygen desaturation of the arterial blood at rest, recent cerebrovascular accident.
Grade 3. Very bad general condition (likely to die): oliguria, intractable heart failure, cachexia by carcinomatosis, coma, etc. (2) Streptokinase Dosage and Control
Before 1965 the initial dose was calculated from the results of the streptokinase reactivity test ; the patients then received about 1,200,000 units during each subsequent 12-hour period. More recently the standard dosage scheme mentioned above has been followed. between the onset of the acute symptoms and the start of treatment. In Table I only cases with an occlusion of the iliac, femoral, or popliteal artery who received at least 106 units of streptokinase were included. Two cases in fact received less than 106 units; in one case the treatment was instituted during half an hour's wait for the surgeon, and in the other the treatment was interrupted after half an hour because of pyrogenic reactions. The frequency of the clearing of iliac, femoral, and popliteal artery occlusions treated with at least 106 units of streptokinase increased when the treatment was started early. Using the x2 test, the frequency of clearing was significantly higher (P<0-001) in patients treated within 72 hours (36/53) than in those treated later (1/14). The same tendency was seen when the occlusion was located in another limb artery, whether an embolus or a thrombus occurred.
(b) Nature of Occlusion.-The distinction between embolus and thrombus was made on clinical grounds as already mentioned. To eliminate the possible influence of the occlusion time only patients with a recent occlusion (<72 hours) of the iliac, femoral, or popliteal artery who received at least 106 units of streptokinase were considered. The occlusion time was in fact slightly but not significantly longer in the patients with thrombi (24 hours) than in those with emboli (16.5 hours), and the clearing ratio was slightly but not significantly lower in patients with thrombi (11/15) compared with emboli (18/24). Nor was a significant difference found when other locations and patients with other occlusion times were considered.
(c) Site of Occlusion.-In considering the clearing ratio according to the location of the thromboembolic occlusion, patients with both emboli and thrombi were included if they were treated with at least 106 units of streptokinase between 12 and 47 hours after the onset of the acute symptoms. The clearing rate of iliac artery obstructions (10/17) was similar to that of femoral and popliteal obstructions (8/14), and hence these groups can be considered together. The higher clearing (c) Nature of Occlusion.-No relation was found between hospital mortality and the nature of the occlusion.
(d) Site of Occlusion.-The mortality was higher in patients with occlusions of the larger arteries (Table VI) . These differences are probably not due to a difference in age of the patients, since the small variations in ages are unlikely to provoke differences in mortality. To evaluate in greater detail the relation between mortality and thrombus location we considered only patients with a general condition of grade 2. Though the 16 patients in this group with an iliac artery occlusion were not older (60.4 years), the mortality rate was higher (8/16) than that in patients with an occlusion in the femoral artery (5/23), whose age averaged 61.6 years.
(e) Degree of Ischaemia.-This was not related to hospital mortality when the general condition was taken into account.
-(f) Clearance of Main Artery.-This was not related to hospital mortality if the other -factors were comparable.
(g) Dose of Streptokinase.-The early mortality (16/85) in six cases was probably due to, or at least precipitated by, the streptokinase infusion; three died of cerebral haemorrhages (one patient had hypertension), one of small-bowel haemorrhage, and two of retroperitoneal haemorrhages (one patient had previously had translumbar aortography). Three of the early deaths were not caused by streptokinase; one patient died of intractable heart failure, one of shock after arteriography, and one of hyperkalaemia and anuria, also after arteriography. Of the remaining seven cases the cause was not clear in five (three of them showed cerebral disturbances before death) and two died after a recent myocardial infarction; the relation between streptokinase treatment and the causes of death in these seven cases was uncertain.
In none of the 14 patients who died later during -their stay in hospital was streptokinase the direct cause of death. It should be stressed that nine patients in this group died of a thromboembolic complication-six of myocardial infarction, two of pulmonary emboli, and in one a large clot was found in the left ventricle. The relation between streptokinase treatment and death from thromboembolic complications in the late hospital period was uncertain. No relation was found between the mortality and the total amount of streptokinase given, but if the patient died early the treatment was interrupted and he received only a few million units.
We therefore evaluated the relation between mortality and initial dose of streptokinase (first half-hour) only in patients with a grade 2 general condition on admission with an iliac, femoral, or popliteal artery occlusion. Though the mean age is not different in the three subgroups, the lowest mortality (0 ,,) was found in the group receiving less than 0-5 X 106 units of streptokinase as initial dose (Table VII) 
Discussion
Our findings were based on a retrospective review and not a planned, controlled, and randomized study; the results should therefore be interpreted with caution. To our knowledge no controlled study on the subject is available. Our results may therefore be compared with other reports and especially that of Hess (1967) , who compiled data on streptokinase treatment in 245 instances of emboli and 193 of thrombi in different European centres, including ours.
In patients treated within the first week after the thromboembolic occlusion of the limb arteries we found a higher frequency of clearing in those treated within 72 hours than those treated later. The same tendency was seen by Hess (1967 Hess (1967) , but these differences were not taken into account. In our study a significantly lower clearing rate (Table II) and significantly higher hospital mortality rate (Table VII) (Verstraete et al., 1966 (Amery et al., 1969) . On the other hand, in trials on the same disease where a lower initial dose of streptokinase was used a difference in favour of streptokinase was reported (Remy et al., 1966; Hiemeyer et al., 1969) . Amputation rate, hospital mortality, and complications other than embolism or bleeding were not considered in the review by Hess (1967) . Embolic complications were reported as the cause of death during streptokinase therapy in 2.3% (3.2% in patients treated for embolic occlusions and 1.5% in thrombotic occlusions). Bleeding was thought to be the cause of death inx 23 out of 458 patients (4.9%); in seven of them cerebral haemorrhage was probably the cause. Furthermore, non-fatal bleeding was reported in 4-1 %.
The higher complication rate in our study could be due to other criteria for evaluating the complication rate, to complications related at least partly to the frequent use of arteriography, to the bad general condition of most of our patients on admission, or to the use of a rather high initial dose of streptokinase.
Since the introduction of Fogarty's catheter (Fogarty et al., 1963 ) the possibilities of vascular surgery have been extended, and this method represents an important alternative for the treatment of patients having the condition under study. An attempt has therefore been made to review published work with the purpose of comparing streptokinase treatment, modern medical therapy, and vascular surgery in patients with recent thromboembolic occlusions of the limb arteries (Amery, 1969 (Klipstein, 1964; Reynolds et al., 1966a Reynolds et al., , 1966b . Megaloblastic anaemia is the most obvious manifestation of this deficiency but it is rare, though a megaloblastic bone marrow may be found in nearly 40%S of treated epileptic patients (Reynolds et al., 1966b) and macrocytosis in the peripheral blood in between 11 and 53%0,x, (Reynolds, 1968) . Phenytoin inhibits folate absorption from folate polyglutamates, a major component of food folate, and possibly folate deficiency is at least partly due to inhibition of intestinal absorption of folates in the diet (Hoffbrand and Necheles, 1968; Rosenberg et al., 1968) .
The clinical consequences of drug-induced folate deficiency have been described by Reynolds (1968 Reynolds ( , 1970 fits has been reported to increase in a significant proportion of patients. Reynolds (1967) studied 26 chronic epileptic patients with folic acid deficiency. Folic acid improved the mental state, but the frequency or severity of fits was increased, necessitating cessation of treatment in nine patients. Other reports include the case of a man of 43 with megaloblastic anaemia due to phenobarbitone in whom administration of folic aicd rapidly precipitated status epilepticus on two occasions (Chanarin et al., 1960 ) and a case reported by Wells (1968) in which the patient died in uncontrolled status epilepticus. Dennis and Taylor (1969) described their experience with 5-mg. tablets of folic acid in children with epilepsy as "alarming" but gave no clinical details. Lanzkowsky et al. (1969) studied an 18-year-old girl with an isolated defect of folic acid absorption associated with mental retardation and cerebral calcification who developed epilepsy. They reported that fits decreased in frequency during folate depletion and increased on folic acid administration, but the degree of change was not stated.
Our clinical impression and that of our colleague, Dr. Neil Gordon (1968) , was that folic acid had little observable effect on either the incidence of seizures or behavioural aspects. This impression was gained both from patients and from children attending the outpatient department. It was therefore decided to carry out a controlled clinical trial to assess a number of values in our patients.
Methods
Preliminary screening of serum folic acid levels in inpatients was carried out, and 51 patients whose serum folate level was less than 3.6 ng./ml. were selected for study, this level being the lower limit for the laboratory concerned. Of
